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Background: Endovascular intervention has become a frequently used treatment of critical limb ischemia (CLI) in recent
times. The recent Bypass vs Angioplasty in Severe Ischaemia of the Leg (BASIL) trial consensus recommended endo-
vascular treatment as a ﬁrst-line treatment in patients who have a life expectancy that was limited to <2 years. Despite
these recommendations, there still remains limited data available to clinicians when seeking to risk stratify patients who
present with CLI. The neutrophil-lymphocyte ratio (NLR) has been suggested to be a marker for predicting mortality and
patency. This study aimed to investigate the use of the NLR as a prognostic marker for primary patency and mortality
after an infrapopliteal endovascular intervention in patients with CLI.
Methods: All patients who underwent tibial angioplasty for CLI were retrospectively analyzed. Demographics, degrees of
stenosis, vessel patency rates, mortality, and comorbidities were recorded. NLRs were calculated from preoperative blood
samples. Primary end points were all-cause mortality, primary patency, and amputation-free survival (AFS) within the
follow-up period of 12 months. Multivariate Cox proportional hazard models were used to identify independent pre-
dictors. Overall survival, AFS, and the probability of a vessel remaining patent were evaluated by standard Kaplan-Meier
survival curves and groups compared by the log-rank test.
Results: Eighty-three patients were monitored for 12 months. Ninety limbs were identiﬁed, with 104 procedural events
and 127 vessels undergoing successful angioplasty. The technical success rate was 86%, and patency at 1 year was 19%.
Survival at 1 year was 76% and AFS was 61%. Patients with a NLR $5.25 had an increased risk of death (hazard ratio,
1.97; 95% conﬁdence interval, 1.08-3.62; P[ .03) compared with those with a NLR of <5.25. Furthermore, those with
lymphocytes counts of <1.5 3 109/L had higher mortality (hazard ratio, 1.88; 95% conﬁdence interval, 1.02-3.70; P[
.045) than those with lymphocyte counts >1.5 3 109/L.
Conclusions: The NLR and absolute lymphocyte counts are potentially valuable prognostic indicators for risk stratiﬁcation
of patient’s presenting with CLI undergoing infrapopliteal angioplasty. (J Vasc Surg 2014;60:661-8.)Critical limb ischemia (CLI) is associated with signiﬁ-
cant morbidity and mortality. If left untreated, the natural
history of CLI is a 25% to 45% chance of major amputa-
tion1 and a 25% chance of death #1 year.2,3 The Bypass
vs Angioplasty in Severe Ischaemia of the Leg (BASIL)
trial,4 although not speciﬁcally looking at tibial interven-
tions, suggested that endovascular intervention should be
considered the primary treatment if life expectancy were
limited to <2 years. Endovascular intervention is becoming
a common approach for CLI associated with infrapopliteal
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://dx.doi.org/10.1016/j.jvs.2014.03.277than long-term patency.5 Endovascular intervention is
considered to be cheaper and safer than bypass, with lower
associated morbidity, mortality, and hospital stays while
achieving limb salvage rates comparable to bypass without
precluding later distal bypass surgery.6-11
Restenosis after treatment is a major limitation of tibial
endovascular therapy. Restenosis rates are high, with re-
ported rates between 30% and 80%12 at 1 year, but clinical
success rates are often higher, with tissue healing persisting
despite reocclusion,5 depending on the length of the
segment involved and the degree of stenosis.
Predicting outcomes after an endovascular intervention
for CLI has proven difﬁcult. An association of diabetes
mellitus, gangrene, and the presence and degree of renal
dysfunction with poor outcomes has been suggested.7,13
The neutrophil-lymphocyte ratio (NLR) is another such
potential prognostic marker identiﬁed as a useful tool in
recognizing patients with potential for adverse outcomes
when treated for CLI. Spark et al14 showed the NLR inde-
pendently predicted death in chronic CLI. The NLR is
thought to be a marker of systemic inﬂammatory burden,
which, if elevated, may lead to more aggressive neointimal
hyperplasia and restenosis.14 However, the NLR has not
been validated as a predictive marker for outcomes in tibial
angioplasty for CLI.661
JOURNAL OF VASCULAR SURGERY
662 Chan et al September 2014The aim of this study was to determine whether NLRs
are a valid prognostic indicator for restenosis, limb salvage,
or death in patients undergoing an endovascular interven-
tion of the infrapopliteal vessel that present as CLI.
METHODS
Ethics approval for this study and the study design was
obtained from the Institutional Review Board. Written
consent was obtained from all patients contributing to
the study.
Study design. The case notes of consecutive patients
treated by the Department of Vascular Surgery in a tertiary
teaching hospital in South Australia were retrospectively
reviewed. All patients who underwent infrapopliteal angio-
plasty for the treatment of CLI between August 2001 and
January 2010 were identiﬁed from the Department of
Vascular Surgery prospectively collected patient informa-
tion system. Patients who had infrapopliteal stents were
excluded from the study.
Patient and laboratory data. Preprocedural and post-
procedural angioplasty images were reviewed, and stenoses
were graded using the TransAtlantic Inter-Society
Consensus (TASC) for the Management of Peripheral
Arterial Disease (TASC II) classiﬁcation.2 The severity of
disease was stratiﬁed according to the Rutherford classiﬁ-
cation.15 Blood samples were taken routinely at pread-
mission clinics for elective interventional cases and at the
time of admission for emergency cases. Demographic
characteristics, laboratory studies, including leukocyte
counts, absolute neutrophil count, and absolute lympho-
cyte counts, were collected from the hospital patient in-
formation system. The NLRs were calculated from the
laboratory data (absolute neutrophil count/absolute
lymphocyte count). Patients were then stratiﬁed by their
NLR as <5.25 or $5.25 according to previous published
reports on the prognostic value of the NLR.14
Interventions and medical therapy. Infrapopliteal in-
terventions were performed using an anterograde or retro-
grade approach at the discretion of the treating physician.
Heparin was routinely administered during all procedures.
After the procedure, routine practice was for patients to be
loaded with 300 mg of clopidogrel and to be discharged on
a 4-week course of combination antiplatelet therapy consist-
ing of aspirin (100 mg) and clopidogrel (75 mg). Adjuvant
medical therapies were prescribed with the end points
targeted according to the recommendations from the
TASC II guidelines.2 These included the use of b-blockers,
antiglycemic therapies, antihypertensives, diuretics, and
cholesterol-lowering medications, as indicated on a patient-
to-patient basis. Nonsteroidal anti-inﬂammatories were not
routinelyprescribed andwereoften contraindicated in light of
renal dysfunction in our population; however, whether they
were prescribed in between follow-up visits was not recorded.
Furthermore, additional wound care clinics and follow-up
was arranged for patients with persistent ulcers, as indicated.
Surveillance protocol. After the interventions, patients
were admitted to the wards for observation and discharged
when deemed medically ﬁt by the treating surgeon. Patientswere routinely followed up at 3-month intervals in outpatient
clinics, at which stage arterial duplex scans were performed to
assess vessel patency. The degree of stenosis was assessed by
measuring the peak systolic velocity (PSV) andcalculating the
peak velocity ratio (intrastenotic PSV divided by the proxi-
mally recorded PSV). A peak velocity ratio of >2.4 was re-
ported as a stenosis of >50% according to Ranke et al.16
These patients then underwent angiography at the discre-
tion of the operating surgeon if ﬁndings correlated clinically.
Complications. Major complications were deﬁned as
access site complication requiring surgery, bleeding com-
plications with a drop in hemoglobin levels of $2 g/dL,
macroembolization requiring further revascularization or
immediate amputation postprocedure. Minor complica-
tions were deﬁned as perioperatively complications that
did not require further recanalization, including superﬁcial
hematoma, minor embolization, and local dissection.
Study end points. Primary outcomes were technical
success, all-cause mortality, 12-month primary patency,
and amputation-free survival (AFS). Technical success was
deﬁned as a successful recanalization with <50% residual
narrowing and restoration of antegrade perfusion as
measured on ultrasound imaging. Primary patency was
deﬁned as uninterrupted patency with no procedure at the
treated site or on a segment adjacent to it.
Statistical analysis. A two-sided log-rank test with an
overall sample size of 83 patients achieved 80% power at a
0.05 signiﬁcance level to detect a minimum hazard ratio
(HR) of 1.8 when the NLRwas$5.25 and aHR of 1.00 for
a NLR of <5.25. Statistical analyses were performed using
STATA 12.0 software (StataCorp LP, College Station,
Tex) and R 2.15.1 software (The R Foundation for Statis-
tical Computing, http://www.r-project.org/foundation/).
Descriptive statistics for interval scale measurements are
expressed as mean and standard deviation, and percentages
were calculated for categoric data.
The outcomes of interest were mortality and primary
patency of vessels attempted. Time to event (survival
time) was calculated in days from the date of the procedure
(baseline) to the survival date, which was date of death, loss
to follow-up, or end of follow-up at 12 months. Kaplan-
Meier survival curves were used to estimate survival rates,
likelihood of limb salvage, and the probability of vessel
patency. Log-rank tests for trend of survival function across
categories of covariates were performed.
Multivariate Cox proportional hazards regression anal-
ysis was applied to calculate the HR for categories of
covariates. The models were adjusted by age, gender,
Rutherford classiﬁcation at presentation, TASC score, pre-
scribing rates, year of intervention, and patient comorbid-
ities, which included ischemic heart disease, chronic renal
insufﬁciency, diabetes mellitus type 2, dyslipidemia, and hy-
pertension. Proportional hazard assumptions for the data
set were also tested and conﬁrmed to satisfy assumptions.
RESULTS
We identiﬁed 83 patients with ischemia affecting 90
limbs. Patient demographics were typical of patients with
Table I. Demographic and clinical characteristics of 83 patients with 104 admissions
Variablea Overall
NLR
Pb<5.25 $5.25
Demographic characteristics
Male 50 (64.9) 25 (55.6) 25 (78.1) .04
Age, years 81.0 (76.0-86.0) 81.0 (75.0-85.0) 82.0 (76.5-86.0) .70
Risk factors (n ¼ 83 patients)
Hypertensionc 42 (54.6) 26 (57.8) 16 (50.0) .50
Ischemic heart disease 49 (63.6) 23 (51.1) 26 (81.3) <.01
Diabetes mellitusd 46 (59.7) 27 (60.0) 19 (59.4) .96
Chronic renal impairmente 12 (15.6) 9 (20.0) 3 (9.4) .21
Dyslipidemiaf 29 (37.7) 17 (37.8) 12 (37.5) .98
Rutherford classiﬁcation
IV 22 (24.8) 11 (19.0) 11 (28.2) .41
V 74 (76.3) 46 (79.3) 28 (71.8) .54
VI 1 (1.0) 1 (1.7) . .
Modiﬁed TASC classiﬁcation
A . . . .
B 2 (2.3) 2 (3.8) . .
C 16 (19.8) 9 (17.0) 7 (26.9) .46
D 61 (77.9) 42 (79.3) 19 (73.1) .74
Disease and intervention
Anterior tibial 41 (42.3) 30 (51.7) 11 (28.2) .02
Posterior tibial 21 (21.7) 11 (19.0) 10 (25.6) .43
Tibioperoneal trunk 31 (32.0) 18 (31.0) 13 (33.3) .81
Peroneal 25 (25.8) 12 (20.7) 13 (33.3) .16
No. of vessels attempted
1 62 (63.9) 37 (63.8) 25 (64.1) .99
2 29 (29.9) 16 (27.6) 13 (33.3) .70
3 6 (6.2) 5 (8.6) 1 (2.6) .
NLR, Neutrophil-lymphocyte ratio; TASC, TransAtlantic Inter-Society Consensus.
aCategoric data are presented as number (%) and continuous data as median (interquartile range).
bP values are based on c2 test for categories and Mann-Whitney U test for age. P values are not available for missing cells: 83 patients for demographic
characteristics and risk factors, 104 admissions for Rutherford classiﬁcation, modiﬁed TASC classiﬁcation, disease and intervention, and number of vessels
attempted.
cDeﬁned as serial blood pressure measurements >140/90 mm Hg.
dDeﬁned as fasting blood glucose test result at or >7.0 mmol/L or a random blood test result at or >11.1 mmol/L.
eDeﬁned as serum creatinine >1.5 mg/dL for >3 months.
fDeﬁned as history of increased low-density lipoprotein or triglycerides, or low high-density lipoprotein or use of lipid-lowering agents, or both.
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had ischemic ulceration or minor gangrene. Of 104 proce-
dures, 71 (68%) angioplasty procedures were performed for
isolated infrapopliteal disease, and the remainder (32%)
involved concurrent angioplasty of the superﬁcal femoral
artery, the popliteal artery, or both. Eight patients under-
went multiple angioplasties, including four with bilateral
disease and 14 with angioplasty on the ipsilateral side.
The tibial vessels that were targeted ranged from a TASC
score of B to D, with 16 unable to be assessed due to un-
availability of imaging. The most common vessel to un-
dergo angioplasty was the anterior tibial artery, followed
by the tibioperoneal trunk and the peroneal artery, with
the posterior tibial least involved. The overall initial tech-
nical success rate for the study was 85%, with 127 of 149
successfully treated lesions.
Survival at 1 year postangioplasty was 76% (Fig 1). AFS
was 68% (Fig 2). Patency rates were 55% at 3 months, 44%
at 6 months, 28% at 9 months, and 19% at 1 year (Fig 3).
Of the 13 failed angioplasty procedures, three limbs (23%)
underwent bypass, and two (15%) required amputation. Incontrast, for the 77 limbs with successful procedures, 14
(18%) had repeat angioplasty, four (5%) had bypass, and
ﬁve (6%) had amputations.
There were no major procedural complications. Of the
23 minor complications, nonocclusive dissections occurred
in nine target vessels (7%), and one patient required super-
ﬁcal femoral artery stenting. Distal embolism occurred in
six patients (5%), who were treated with suction embolec-
tomy and glyceryl trinitrate. A postprocedural hematoma
developed in ﬁve patients (4%), and all were treated conser-
vatively. An arteriovenous ﬁstula formed at the treated
segment in two patients (2%), without any clinical conse-
quence. One anterior tibial artery (1%) was perforated.
None of the minor complications were associated with any
signiﬁcant clinical consequences and did not require any
further revascularization.
Patients with a NLR of$5.25 had a 12-month mortality
risk that was nearly double that of those with aNLRof<5.25
(1-year mortality of 39% vs 17%; respectively; HR, 1.97;
95% conﬁdence interval [CI], 1.08-3.62; P ¼ .03; Fig 4).
Similarly, those with lymphocytes counts of <1.5  109/L
Fig 1. Kaplan-Meier life table shows overall survival in the 12 months after infrapopliteal endovascular intervention
with angioplasty for critical limb ischemia (CLI). The standard error for the calculated Kaplan-Meier curves
remained <10% at the 12-month follow-up.
Fig 2. Amputation-free survival (AFS) is shown for the 12 months after infrapopliteal angioplasty for critical limb
ischemia (CLI). The standard error for the calculated Kaplan-Meier curves (gray area) remained <10% at the 12-
month follow-up.
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with those with lymphocyte counts >1.5  109/L (36% vs
14%, respectively; HR, 1.88; 95% CI, 1.02-3.70; P ¼ .045;
Fig 5). A high NLR was associated with a higher risk of
the patient having ischemic heart disease (P < .01) and
disease involving the anterior tibial artery (P ¼ .02; Table I).
No statistical signiﬁcance was demonstrated when strat-
iﬁed by absolute neutrophil count (HR, 1.19; 95% CI,
0.63-2.25; P ¼ .61). Furthermore, primary patency at
1 year for the cohort showed no signiﬁcant difference
when stratiﬁed by NLR (HR, 1.03; 95% CI, 0.74-1.43;
P ¼ .87), lymphocyte (HR, 1.02; 95% CI, 0.73-1.43;
P ¼ .91), and neutrophil counts (HR, 0.86; 95% CI,
0.58-1.28; P ¼ .47; Table II). The standard error for calcu-
lated Kaplan-Meier curves remained<10% at the 12-month
follow-up for overall survival, AFS, and patency. However,
the standard error for the survival curves was 14.4% in the
group with a lymphocyte count of 1.5 to 3.5 109/L.
Analysis with a multivariate model looking at patient
demographics and comorbidities identiﬁed no signiﬁcantassociation (Table I). However, during the 8 years, there
was a signiﬁcant difference in the severity of the Rutherford
classiﬁcation at presentation, with the latter 5 years
showing an increased incidence for patients presenting
with more severe symptoms of CLI being offered angio-
plasty over open procedures. Despite this increase in CLI
severity, mortality rates did not differ signiﬁcantly. Pre-
scribing practice of drug classes was consistent, with no sig-
niﬁcant differences identiﬁed over the time period;
however, there was some variability in some of the
preferred speciﬁc agents within the classes (ie, simvastatin
vs atorvastatin, etc).
DISCUSSION
Clinical decision making and planning for revasculari-
zation is difﬁcult in patients presenting with CLI because
of severe multiorgan comorbid disease associated with its
presentation. Therefore, the identiﬁcation and implemen-
tation of prognostic indicators is greatly beneﬁcial to the
clinician. Being able to identify patients who are at high
Fig 3. Overall patency is shown after infrapopliteal angioplasty for critical limb ischemia (CLI). Patency of vessels was
adjudged by ultrasound imaging follow-up at 3 months. The standard error for calculated Kaplan-Meier curves (gray
area) remained <10% at the 12-month follow-up.
Fig 4. Survival stratiﬁed by a neutrophil-lymphocyte ratio (NLR) of <5.25 (dotted line) and $5.25 (solid line) in
patients after infrapopliteal angioplasty for critical limb ischemia (CLI) shows signiﬁcance between a NLR $5.25 and
an increased risk of death. The standard error for calculated Kaplan-Meier curves (gray area) remained <10% at the 12-
month follow-up. CI, Conﬁdence interval; HR, hazard ratio.
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ments, such as endovascular intervention, for initial limb
salvage. This study found a signiﬁcant relationship between
a high NLR and increased mortality at 1 year for patients
with CLI undergoing tibial angioplasty.
In the setting of coronary artery disease especially, the
NLR has emerged as a powerful predictor of outcome.
A high NLR has been shown to be predictive not only
for bare-metal stent restenosis17 and progression of athero-
sclerosis in the coronary arteries18 but, more signiﬁcantly,
also for death after percutaneous coronary intervention
and coronary artery bypass grafting.19 Our study suggests
that NLR may also correlate with the presence of ischemic
heart disease in patients who present with CLI.
In the context of peripheral vascular disease, Bhutta
et al20 retrospectively analyzed 1021 patients who under-
went major vascular surgery (open or endovascular aortic
aneurysm repair, lower limb revascularization, or carotid
endarterectomy) and found that a preoperative NLR of>5 identiﬁed patients at increased risk of death #2 years.
Furthermore, Kullar et al21 found that the postoperative
NLR was an independent predictor of graft failure in 126
patients.
Spark et al14 have been the only group to investigate
the value of the NLR in CLI that included endovascular
intervention. In their prospective study of 149 patients pre-
senting with CLI, they found that a preprocedural NLR
$5.25 was associated with higher mortality. Our ﬁndings
correlate with this and suggest that the NLR could also
be applied to infrapopliteal vessel angioplasty, with similar
correlations in regards to adverse outcomes.
In addition, our study has been the ﬁrst to show that
lymphopenia is related to higher risks of death but not pri-
mary patency after intervention. In cardiac disease, a low
lymphocyte count has been shown to be an independent
prognostic marker in heart failure,22 with a suggestion
that patients with lower lymphocyte counts tend to be
older and have higher rates of comorbid disease,23
Fig 5. Survival stratiﬁed by absolute lymphocyte count of <1.5  109/L (dotted line) and 1.5 to 3.5 109/L (solid
line) in patients after infrapopliteal angioplasty for critical limb ischemia (CLI) shows lymphocytosis is a predictor for
death. The standard error for the calculated Kaplan-Meier curves (gray area) of patients with lymphocytes at 1.5 to
3.5 109/L was 14.4% at 12 months. CI, Conﬁdence interval; HR, hazard ratio.
Table II. Cox proportional hazard model for survival
status and patencya
Variable HR 95% CI P
Survival
NLR
<5.25 1 . .
$5.25 1.97 1.08-3.62 .03
Lymphocytes, 109/L
<1.5 1 . .
1.5-3.5 0.53 0.27-0.98 .045
Neutrophils, 109/L
1.8-7.5 1 . .
>7.5 1.19 0.63-2.25 .61
Patency
NLR
<5.25 1 . .
$5.25 1.03 0.74-1.43 .87
Lymphocytes, 109/L
<1.5 1 . .
1.5-3.5 1.02 0.73-1.43 .91
Neutrophils, 109/L
1.8-7.5 1 . .
>7.5 0.86 0.58-1.28 .47
AFS
NLR
<5.25 1 . .
$5.25 1.86 0.83-4.14 .13
Lymphocytes, 109/L
<1.5 1 . .
1.5-3.5 0.54 0.24-1.25 .15
Neutrophils, 109/L
1.8-7.5 1 . .
>7.5 1.37 0.55-3.39 .5
AFS, Amputation free survival; CI, conﬁdence interval; HR, hazard ratio;
NLR, neutrophil-lymphocyte ratio.
aThe models were adjusted by patients’ demographics (age and gender) and
clinical characteristics (hypertension, ischemic heart disease, diabetes melli-
tus, creatinine, Rutherford classiﬁcation, and number of vessels attempted).
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ﬁbrillation.19,20 This burden of comorbid disease is also
prevalent in our population of patients, with diabetes pre-
sent in nearly 50% and periprocedural renal dysfunction
in just over 60%. Furthermore, these factors have beenpreviously identiﬁed as being associated with poor outcome
after vascular intervention6,12 and thus may be reﬂected in
a higher risk of death.
We believe that tibial disease may reﬂect a more
aggressive disease process (ie, with greater oxidative free
radicals, greater circulating proinﬂammatory cytokines,
etc), with the relative lymphopenia a result of a greater
cortisol-induced stress response, and although outside of
the scope of this study, it would also be interesting to
see whether this lymphopenia translates to an increased
risk of other infections, respiratory or otherwise, in this
group of patients.
No relationship was found between the absolute
neutrophil count and primary patency or mortality. This
contrasts with a number of studies that have demonstrated
that neutrophils are a strong marker to predict adverse car-
diovascular outcomes. Toor et al24 retrospectively studied
101 patients who underwent percutaneous transluminal
angioplasty and found that preprocedural neutrophils
could be used as a global risk factor for adverse outcomes
after the procedure. Neutrophils mediate the inﬂammatory
response after vascular injury and have been shown to accu-
mulate at the sites of angioplasty#1 hour postprocedure.25
In animal models, this accumulation of neutrophils has
been reported to promote intimal hyperplasia,26 with the
localized inﬂammation resulting in subsequent thrombus
formation, intimal hyperplasia development, and potential
restenosis.25 Joviliano et al25 suggested that the value of
the NLR is that it reﬂects the neutrophilia of inﬂammation
and the relative lymphopenia of cortisol-induced stress.
The results of our study do not dispute this but may sug-
gest that lymphopenia may have a larger role in predicting
adverse outcomes than ﬁrst thought.
Our study achieved an AFS rate of 68% at 1 year, which
is comparable to current standards reported to be between
75% and 100%.5,27 Similarly, our 1-year survival rate was
76%, which is also comparable to the 65% to 78% reported
in the literature. Nair et al5 suggested that clinical success is
often higher than long-term primary patency rates because
healing of wounds can occur in 3 to 6 months and persist
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good AFS despite relatively poor primary patency.
If NLR is correlated with poorer outcomes, how
should clinicians approach patients with ratios $5.25? Un-
fortunately, there is currently no evidence in the literature
to guide how to directly affect this measure. NLR is a
reﬂection of the systemic inﬂammatory burden created
by the systemic disease state of atherosclerosis. We know
that pharmacotherapy, such as with aspirin and statins,
which are recommended for the treatment of atheroscle-
rotic risk factors, also have pleiotropic anti-inﬂammatory
properties that have seen their use proposed as an adjuvant
treatment for patients with sepsis.28 In atherosclerosis in
particular, high-dose statin therapy has been demonstrated
to exert anti-inﬂammatory effects, modulate endothelial
function, and inhibit the thrombotic signaling cascade
and has the potential to lead to plaque/disease regres-
sion.29,30 As an extension of this idea, one could speculate
that maximizing secondary prevention with pharmaco-
therapy may also be likely to reduce NLR. However,
further work is required to deﬁne and conﬁrm this
concept, which unfortunately falls outside the scope of
this study.
Further limitations of this study were its retrospective
design, and further prospective trials are required to further
elucidate the value of the NLR in the setting of peripheral
vascular disease. Furthermore, due the limited sample size,
there may be type II statistical error when not having found
correlations among NLR, lymphocytes, and neutrophils
with patency.
Despite these limitations, NLR represents an attractive
test for clinicians as a risk assessment model, especially
given the simplicity and ready availability of the neutrophil
and lymphocyte counts as a preoperative workup. We
recommend that an NLR be calculated for all patients pre-
senting with CLI. Those who are undergoing endovascular
procedures and have a high preprocedural NLR or lympho-
penia are at higher risk and may warrant aggressive preop-
erative optimization of risk factors and more diligent
follow-up.
CONCLUSIONS
The preprocedural NLR may represent a valuable
prognostic marker of increased risk of death after infrapo-
pliteal angioplasty for CLI. Our retrospective study demon-
strated an independent correlation between an increased
NLR and lymphopenia with a greater risk of death. This
study suggests that NLR and lymphocyte counts may be
valid tools to risk stratify patients being considered for tibial
angioplasty. However, further prospective trials are
required to elucidate the validity of this measurement.
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